Brief: Bionomics Receives FDA Clearance Of IND For Evaluation Of BNC210 In A Phase 2 Social Anxiety Disorder Prevail Study

Bionomics

01/11/2021 10:15

Nov 1 (Reuters) - Bionomics Ltd  BNO.AX :
    * BIONOMICS RECEIVES FDA CLEARANCE OF IND FOR EVALUATION OF
BNC210
IN A PHASE 2 SOCIAL ANXIETY DISORDER PREVAIL STUDY
    * BIONOMICS LTD - PREVAIL STUDY REMAINS ON TARGET TO
INITIATE BY
END OF 2021 AND IS EXPECTED TO READ OUT TOPLINE DATA BY END OF
2022

Source text for Eikon:  ID:nPn3d6VMYa 
Further company coverage:  BNO.AX 

 ((Reuters.Briefs@thomsonreuters.com;))